PURPOSE: Necroptosis has been proposed as a mode of cell death that is a caspase-independent programmed necrosis. We investigated whether necroptosis is involved in myocardial ischemia-reperfusion injury in isolated guinea pig hearts and, if so, whether simultaneous inhibition of necroptosis and apoptosis confers enhanced cardioprotection. METHODS: Isolated perfused guinea pig hearts were subjected to 30 min ischemia and 4 h reperfusion (control = CTL, n = 8). Necrostatin-1 (necroptosis inhibitor, 10 μM), Z-VAD (apoptosis inhibitor, 0.1 μM) and both inhibitors were administered starting 5 min before ischemia and during the initial 30 min of reperfusion (Nec, Z-VAD, Nec + Z-VAD; n = 8 each). Contractile recovery was monitored by left ventricular developed (LVDP) and end-diastolic (LVEDP) pressure. Infarct size was determined by triphenyltetrazolium chloride staining. Tissue samples were obtained after 4 h reperfusion to determine expression of receptor-interacting protein 1 (RIP1) and activated caspase 3 by Western blot analysis. RESULTS: After reperfusion, Nec + Z-VAD had higher LVDP and lower LVEDP compared with CTL. Infarct size was reduced in Nec and Z-VAD compared with CTL. Combination of necroptosis and apoptosis inhibition further reduced infarct size. Expression of activated caspase 3 was not increased in Z-VAD and Nec + Z-VAD compared with Nec and CTL. Expression of RIP1 was preserved in Z-VAD and Nec + Z-VAD compared with CTL, suggesting RIP1-mediated necrosis is involved in myocardial ischemia-reperfusion injury. CONCLUSION: Necroptosis is involved in myocardial ischemia-reperfusion injury, and simultaneous inhibition of necroptosis and apoptosis enhances the cardioprotective effect. These findings may provide a novel, additive strategy for cardioprotection in acute myocardial infarction.
PURPOSE: Necroptosis has been proposed as a mode of cell death that is a caspase-independent programmed necrosis. We investigated whether necroptosis is involved in myocardial ischemia-reperfusion injury in isolated guinea pig hearts and, if so, whether simultaneous inhibition of necroptosis and apoptosis confers enhanced cardioprotection. METHODS: Isolated perfused guinea pig hearts were subjected to 30 min ischemia and 4 h reperfusion (control = CTL, n = 8). Necrostatin-1 (necroptosis inhibitor, 10 μM), Z-VAD (apoptosis inhibitor, 0.1 μM) and both inhibitors were administered starting 5 min before ischemia and during the initial 30 min of reperfusion (Nec, Z-VAD, Nec + Z-VAD; n = 8 each). Contractile recovery was monitored by left ventricular developed (LVDP) and end-diastolic (LVEDP) pressure. Infarct size was determined by triphenyltetrazolium chloride staining. Tissue samples were obtained after 4 h reperfusion to determine expression of receptor-interacting protein 1 (RIP1) and activated caspase 3 by Western blot analysis. RESULTS: After reperfusion, Nec + Z-VAD had higher LVDP and lower LVEDP compared with CTL. Infarct size was reduced in Nec and Z-VAD compared with CTL. Combination of necroptosis and apoptosis inhibition further reduced infarct size. Expression of activated caspase 3 was not increased in Z-VAD and Nec + Z-VAD compared with Nec and CTL. Expression of RIP1 was preserved in Z-VAD and Nec + Z-VAD compared with CTL, suggesting RIP1-mediated necrosis is involved in myocardial ischemia-reperfusion injury. CONCLUSION: Necroptosis is involved in myocardial ischemia-reperfusion injury, and simultaneous inhibition of necroptosis and apoptosis enhances the cardioprotective effect. These findings may provide a novel, additive strategy for cardioprotection in acute myocardial infarction.
Authors: Keith D Garlid; Alexandre D T Costa; Casey L Quinlan; Sandrine V Pierre; Pierre Dos Santos Journal: J Mol Cell Cardiol Date: 2008-12-11 Impact factor: 5.000
Authors: N Holler; R Zaru; O Micheau; M Thome; A Attinger; S Valitutti; J L Bodmer; P Schneider; B Seed; J Tschopp Journal: Nat Immunol Date: 2000-12 Impact factor: 25.606
Authors: Christopher C T Smith; Sean M Davidson; Shiang Y Lim; James C Simpkin; John S Hothersall; Derek M Yellon Journal: Cardiovasc Drugs Ther Date: 2007-07-31 Impact factor: 3.727
Authors: D E Christofferson; Y Li; J Hitomi; W Zhou; C Upperman; H Zhu; S A Gerber; S Gygi; J Yuan Journal: Cell Death Dis Date: 2012-06-14 Impact factor: 8.469
Authors: Jia Liu; Alain van Mil; Krijn Vrijsen; Jiajun Zhao; Ling Gao; Corina H G Metz; Marie-José Goumans; Pieter A Doevendans; Joost P G Sluijter Journal: J Cell Mol Med Date: 2010-06-09 Impact factor: 5.310
Authors: Sarah M Beno; Ashleigh N Riegler; Ryan P Gilley; Terry Brissac; Yong Wang; Katherine L Kruckow; Jeevan K Jadapalli; Griffin M Wright; Anukul T Shenoy; Sara N Stoner; Marcos I Restrepo; Jessy S Deshane; Ganesh V Halade; Norberto González-Juarbe; Carlos J Orihuela Journal: J Infect Dis Date: 2020-11-09 Impact factor: 5.226
Authors: Robert A Kloner; David A Brown; Marie Csete; Wangde Dai; James M Downey; Roberta A Gottlieb; Sharon L Hale; Jianru Shi Journal: Nat Rev Cardiol Date: 2017-07-27 Impact factor: 32.419